NEW
YORK, Jan. 9, 2023 /PRNewswire/ -- Elevation
Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company
focused on the discovery and development of selective cancer
therapies to treat patients across a range of solid tumors with
significant unmet medical needs, today announced that Joseph Ferra, Interim Chief Executive Officer
and Chief Financial Officer of Elevation Oncology, will present at
the 41st Annual J.P. Morgan Healthcare Conference on
Thursday, January 12, 2023 at
9:45 am PT.
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology,
Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class, antibody drug conjugate
(ADC) designed to target Claudin18.2, a clinically validated
molecular target that can selectively deliver a cytotoxic payload
directly to kill cancer cells. We are working to rapidly advance
EO-3021 into the clinic in the US across a range of solid tumor
indications to demonstrate its potential, as well as exploring
other opportunities through new or existing partnerships and
business development opportunities to expand our novel oncology
pipeline. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media
Contact
Candice Masse,
978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301715935.html
SOURCE Elevation Oncology